

Attorney Docket No.: **ISPH-0752**  
Serial No.: **10/630,399**  
Page 4

**REMARKS**

Claims 1, 2 and 4-15 are pending in the instant application. An Office Action has restricted the pending claims into the following groups:

Group I: Claims 1, 2 and 4-14, drawn to antisense compounds targeted to IL-1 receptor-associated kinase-4;

Group II: Claim 15, drawn to methods of inhibiting the expression of inhibitor IL-1 receptor-associated kinase-4.

The Applicants elect Group I, claims 1, 2 and 4-14, without traverse. The Applicants have withdrawn claim 15 as suggested by the Examiner. All of the limitations of claim 1 were already incorporated into the claim so that it may be considered for rejoinder upon allowance of claim 1.

**I. Fees**

It is believed that no fee is due with this response. However, if an additional fee is due, the Commissioner is hereby entitled to charge the fee to the Deposit Account 500252, referencing case ISPH-0752.

**II. Conclusion**

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. Accordingly, an early office action on the merits of the case is respectfully requested.

Respectfully submitted,



Colleen J. McKiernan, PhD  
Registration No. 48,570

Date: *March 10, 2005*

Isis Pharmaceuticals  
2922 Faraday Avenue  
Carlsbad, CA 92008

Phone: 760-603-2722  
Facsimile: 760-603-3820